Company Profile

Advanced Cancer Therapeutics LLC
Profile last edited on: 2/21/19      CAGE: 54BJ0      UEI:

Business Identifier: Discovery and early development of novel cancer therapeutics
Year Founded
2007
First Award
2012
Latest Award
2012
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 East Market Street Suite 280
Louisville, KY 40202
Location: Single
Congr. District: 03
County: Jefferson

Public Profile

Anchored in work licensed from University of Louisville, Advanced Cancer Therapeutics (ACT) is a biotechnology company tackling discovery and early development of cancer therapeutics with commercialization and manufacturing of the most promising discoveries. The firm is developing a pipeline of anti-cancer products, including MIF, a macrophage migration inhibitory factor; PU27, a synthetic oligonucleotide that is used as an anticancer compound; PFKFB3, a small molecule compound; CK37, a small molecule that inhibits cell proliferation, choline kinase enzymatic activity, and tumor growth; and a vaccine for human papilloma virus, which is caused for cervical cancer. The firm obtained exclusive licenses to four anti-cancer therapeutics and one pharmaceutical vaccine for human papillomavirus (HPV), all derived from tobacco plants. This may provide patients broad protection against many strains of HPV, as well as provide a cost-effective alternative to existing HPV vaccines on the market today. In 2017 it was loally reported that the results of important trials were disappoiting andmya have resulted in a wind down of the firm's operations

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 1 NIH $157,920
Project Title: Pfk-015: An Inhibitor Of Pfkfb3 To Treat Glioblastomas

Key People / Management

  Randall B Riggs -- President; Chief Executive Officer

  Tyree G Wilburn -- Co-founder, CEO and President

  Gilles H Tapolsky -- Chief Scientific Officer